HomeCompareTKCOF vs ABBV

TKCOF vs ABBV: Dividend Comparison 2026

TKCOF yields 3.81% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TKCOF wins by $1403.06M in total portfolio value· pulled ahead in Year 2
10 years
TKCOF
TKCOF
● Live price
3.81%
Share price
$9.26
Annual div
$0.35
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1403.16M
Annual income
$1,335,861,405.29
Full TKCOF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TKCOF vs ABBV

📍 TKCOF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTKCOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TKCOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TKCOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TKCOF
Annual income on $10K today (after 15% tax)
$324.10/yr
After 10yr DRIP, annual income (after tax)
$1,135,482,194.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, TKCOF beats the other by $1,135,460,327.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TKCOF + ABBV for your $10,000?

TKCOF: 50%ABBV: 50%
100% ABBV50/50100% TKCOF
Portfolio after 10yr
$701.63M
Annual income
$667,943,565.50/yr
Blended yield
95.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TKCOF
No analyst data
Altman Z
2.9
Piotroski
8/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TKCOF buys
0
ABBV buys
0
No recent congressional trades found for TKCOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTKCOFABBV
Forward yield3.81%3.12%
Annual dividend / share$0.35$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$1403.16M$104.7K
Annual income after 10y$1,335,861,405.29$25,725.73
Total dividends collected$1398.33M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TKCOF vs ABBV ($10,000, DRIP)

YearTKCOF PortfolioTKCOF Income/yrABBV PortfolioABBV Income/yrGap
1$11,463$762.59$11,559$438.51$96.00ABBV
2← crossover$13,899$1,633.88$13,494$640.86+$405.00TKCOF
3$18,575$3,703.08$15,951$945.97+$2.6KTKCOF
4$29,125$9,250.31$19,152$1,413.89+$10.0KTKCOF
5$58,275$27,111.22$23,443$2,146.38+$34.8KTKCOF
6$163,748$101,393.15$29,391$3,321.96+$134.4KTKCOF
7$707,741$532,531.15$37,948$5,265.87+$669.8KTKCOF
8$5,059,479$4,302,196.22$50,795$8,596.74+$5.01MTKCOF
9$62,900,386$57,486,743.48$71,034$14,549.41+$62.83MTKCOF
10$1,403,164,819$1,335,861,405.29$104,715$25,725.73+$1403.06MTKCOF

TKCOF vs ABBV: Complete Analysis 2026

TKCOFStock

Toho Co., Ltd. engages in the motion picture, theatrical production, and real estate businesses in Japan. It is involved in producing, buying/selling, and renting movies; producing and selling television programs, movie pamphlets, and video software; and business related to merchandising rights, and other activities. The company also engages in the planning, production, and performance of stage productions; and leasing of land/buildings, and others. Toho Co., Ltd. was incorporated in 1932 and is based in Tokyo, Japan.

Full TKCOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TKCOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TKCOF vs SCHDTKCOF vs JEPITKCOF vs OTKCOF vs KOTKCOF vs MAINTKCOF vs JNJTKCOF vs MRKTKCOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.